{"success":true,"data":{"pressRelease":{"id":"17603","rtpr_id":"nGNX4QngfM","ticker":"EQ","exchange":"NASDAQ","all_tickers":["EQ"],"title":"Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","published_at":"2026-05-01T20:42:32.114Z","article_body":"LA JOLLA, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq:\nEQ), a biotechnology innovator developing novel therapies to treat severe\nautoimmune and inflammatory disorders, today announced that on May 1, 2026,\nthe Compensation Committee of Equillium’s Board of Directors granted\ninducement awards consisting of nonstatutory stock options to purchase an\naggregate of 800,000 shares of common stock to two new employees under\nEquillium’s 2024 Inducement Plan. The Compensation Committee approved the\nstock option grants as an inducement material to such employees’ employment\nin accordance with Nasdaq Listing Rule 5635(c)(4).\n\nEach stock option has an exercise price per share equal to $2.08,\nEquillium’s closing stock price on May 1, 2026, and will vest over four\nyears, with 25% of the underlying shares vesting on the one-year anniversary\nof the applicable vesting commencement date and the balance of the underlying\nshares vesting monthly thereafter over 36 months, subject to the new\nemployee’s continued service relationship with Equillium through the\napplicable vesting dates. The stock option is subject to the terms and\nconditions of Equillium’s 2024 Inducement Plan and the terms and conditions\nof an applicable stock option agreement covering the grant.\n\nAbout Equillium\nEquillium is a biotechnology innovator developing novel therapies to treat\nsevere autoimmune and inflammatory disorders. The company’s lead therapeutic\ncandidate is EQ504, a potent and selective aryl hydrocarbon receptor (AhR)\nmodulator designed with a multi-modal, non-immunosuppressive mechanism of\naction to be complementary to other inflammation and immunology agents. EQ504\nis an investigational therapeutic program with potential for targeted, local\ndelivery via enteric coating for the treatment of ulcerative colitis and other\ngastrointestinal diseases or inhaled formulations for the treatment of\ninflammatory lung diseases.\n\nFor more information, visit www.equilliumbio.com.\n\nForward Looking Statements \nStatements contained in this press release regarding matters that are not\nhistorical facts are \"forward-looking statements\" within the meaning of the\nPrivate Securities Litigation Reform Act of 1995. Forward-looking statements\nmay be identified by the use of words such as \"anticipate\", \"believe\",\n“could”, “continue”, \"expect\", \"estimate\", “may”, \"plan\",\n\"outlook\", “future” and \"project\" and other similar expressions that\npredict or indicate future events or trends or that are not statements of\nhistorical matters. Because such statements are subject to risks and\nuncertainties, many of which are outside of Equillium’s control, actual\nresults may differ materially from those expressed or implied by such\nforward-looking statements. Risks that contribute to the uncertain nature of\nthe forward-looking statements include: Equillium’s ability to execute its\nplans and strategies; risks related to performing clinical studies; and\nwhether the results from clinical studies will validate and support the safety\nand efficacy of Equillium’s product candidates. These and other risks and\nuncertainties are described more fully under the caption \"Risk Factors\" and\nelsewhere in Equillium's filings and reports, which may be accessed for free\nby visiting the Securities and Exchange Commission’s website at www.sec.gov\nand on Equillium’s website under the heading “Investors.” Investors\nshould take such risks into account and should not rely on forward-looking\nstatements when making investment decisions. All forward-looking statements\ncontained in this press release speak only as of the date on which they were\nmade. Equillium undertakes no obligation to update such statements to reflect\nevents that occur or circumstances that exist after the date on which they\nwere made, except as required by law.\n\nInvestor Contact \nPJ Kelleher\nLifeSci Advisors, LLC\n+1-617-430-7579\npkelleher@lifesciadvisors.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/14ce766d-e697-461f-a27c-c1ee49c0eeff)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4QngfM","title":"Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","ticker":"EQ","created":"2026-05-01T20:42:32.114Z","tickers":["EQ"],"exchange":"NASDAQ","article_body":"LA JOLLA, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq:\nEQ), a biotechnology innovator developing novel therapies to treat severe\nautoimmune and inflammatory disorders, today announced that on May 1, 2026,\nthe Compensation Committee of Equillium’s Board of Directors granted\ninducement awards consisting of nonstatutory stock options to purchase an\naggregate of 800,000 shares of common stock to two new employees under\nEquillium’s 2024 Inducement Plan. The Compensation Committee approved the\nstock option grants as an inducement material to such employees’ employment\nin accordance with Nasdaq Listing Rule 5635(c)(4).\n\nEach stock option has an exercise price per share equal to $2.08,\nEquillium’s closing stock price on May 1, 2026, and will vest over four\nyears, with 25% of the underlying shares vesting on the one-year anniversary\nof the applicable vesting commencement date and the balance of the underlying\nshares vesting monthly thereafter over 36 months, subject to the new\nemployee’s continued service relationship with Equillium through the\napplicable vesting dates. The stock option is subject to the terms and\nconditions of Equillium’s 2024 Inducement Plan and the terms and conditions\nof an applicable stock option agreement covering the grant.\n\nAbout Equillium\nEquillium is a biotechnology innovator developing novel therapies to treat\nsevere autoimmune and inflammatory disorders. The company’s lead therapeutic\ncandidate is EQ504, a potent and selective aryl hydrocarbon receptor (AhR)\nmodulator designed with a multi-modal, non-immunosuppressive mechanism of\naction to be complementary to other inflammation and immunology agents. EQ504\nis an investigational therapeutic program with potential for targeted, local\ndelivery via enteric coating for the treatment of ulcerative colitis and other\ngastrointestinal diseases or inhaled formulations for the treatment of\ninflammatory lung diseases.\n\nFor more information, visit www.equilliumbio.com.\n\nForward Looking Statements \nStatements contained in this press release regarding matters that are not\nhistorical facts are \"forward-looking statements\" within the meaning of the\nPrivate Securities Litigation Reform Act of 1995. Forward-looking statements\nmay be identified by the use of words such as \"anticipate\", \"believe\",\n“could”, “continue”, \"expect\", \"estimate\", “may”, \"plan\",\n\"outlook\", “future” and \"project\" and other similar expressions that\npredict or indicate future events or trends or that are not statements of\nhistorical matters. Because such statements are subject to risks and\nuncertainties, many of which are outside of Equillium’s control, actual\nresults may differ materially from those expressed or implied by such\nforward-looking statements. Risks that contribute to the uncertain nature of\nthe forward-looking statements include: Equillium’s ability to execute its\nplans and strategies; risks related to performing clinical studies; and\nwhether the results from clinical studies will validate and support the safety\nand efficacy of Equillium’s product candidates. These and other risks and\nuncertainties are described more fully under the caption \"Risk Factors\" and\nelsewhere in Equillium's filings and reports, which may be accessed for free\nby visiting the Securities and Exchange Commission’s website at www.sec.gov\nand on Equillium’s website under the heading “Investors.” Investors\nshould take such risks into account and should not rely on forward-looking\nstatements when making investment decisions. All forward-looking statements\ncontained in this press release speak only as of the date on which they were\nmade. Equillium undertakes no obligation to update such statements to reflect\nevents that occur or circumstances that exist after the date on which they\nwere made, except as required by law.\n\nInvestor Contact \nPJ Kelleher\nLifeSci Advisors, LLC\n+1-617-430-7579\npkelleher@lifesciadvisors.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/14ce766d-e697-461f-a27c-c1ee49c0eeff)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-01T20:42:32.147515933Z","server_sent_at_ms":1777668152147},"received_at":"2026-05-01T20:42:32.199Z","source_url":"https://www.globenewswire.com/news-release/2026/04/02/3267820/0/en/equillium-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html"},"analysis":{"id":"12898","press_release_id":"17603","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Equillium granted inducement awards of 800,000 nonstatutory stock options to two new employees under its 2024 Inducement Plan.\n\nThe options have an exercise price of $2.08 per share, equal to the closing price on the grant date, and vest over four years.\n\nThese grants were approved by the Compensation Committee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine inducement grants to new hires; no material impact."},"keyFigures":{"offeringPrice":2.08,"sharesOffered":800000},"quotedText":"","namedEntities":{"people":[{"name":"PJ Kelleher","role":"Investor Contact"}],"products":["EQ504"],"companies":[{"name":"Equillium, Inc.","ticker":"EQ"},{"name":"LifeSci Advisors, LLC","relationship":"Investor Relations"}],"dollarAmounts":[{"amount":"$2.08","context":"exercise price per share / closing stock price on May 1, 2026"}]},"materialImpact":{"score":1,"reasoning":"Routine 8-K style disclosure of inducement grants to new employees. The grants are at-the-money (exercise price equals closing price) and standard vesting applies. No change in business strategy, financial results, or material corporate structure."},"tickerRelevance":{"others":[],"primary":"EQ"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small/micro-cap","eventGravity":"routine_compensation_disclosure","sectorWeight":"biotech"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Equillium granted inducement awards of 800,000 nonstatutory stock options to two new employees under its 2024 Inducement Plan.\n\nThe options have an exercise price of $2.08 per share, equal to the closing price on the grant date, and vest over four years.\n\nThese grants were approved by the Compensation Committee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).","key_figures":{"offeringPrice":2.08,"sharesOffered":800000},"named_entities":{"people":[{"name":"PJ Kelleher","role":"Investor Contact"}],"products":["EQ504"],"companies":[{"name":"Equillium, Inc.","ticker":"EQ"},{"name":"LifeSci Advisors, LLC","relationship":"Investor Relations"}],"dollarAmounts":[{"amount":"$2.08","context":"exercise price per share / closing stock price on May 1, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-01T20:55:50.138Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"small/micro-cap","eventGravity":"routine_compensation_disclosure","sectorWeight":"biotech"}},"durationMs":128892,"modelName":"glm-4.7"}}